DNAnexus announce software to streamline chemical trials
19 February 2018
DNAnexus has announced a software solution which focuses on next-generation sequencing (NGS) driven adaptive trial design to optimise and reduce the risk of clinical trials
In January 2020 the American Diabetes Association released a new set of clinical standards that, for the first time, included the use of an FDA-approved autonomous artificial intelligence (AI) platform for detecting diabetic retinopathy in people with diabetes.
